Belli, Carmen http://orcid.org/0000-0001-7067-7496
Repetto, Matteo
Anand, Santosh
Porta, Camillo
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Article History
Received: 17 October 2022
Revised: 31 January 2023
Accepted: 24 February 2023
First Online: 13 March 2023
Competing interests
: MR reports travelling funding for Sanofi. CP remunerated Consultant and/or Speaker for: Angelini Pharma, AstraZeneca, BMS, Eisai, General Electric, Ipsen, MSD; Protocol Steering Committee Member for: BMS, Eisai and MSD. VS reports research grants from Eli Lilly/Loxo Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals, and Helsinn Pharmaceuticals, and a grant and an advisory board/consultant positions with Eli Lilly/Loxo Oncology during the conduct of the study, as well as research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berg Health, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, AbbVie, Alfasigma, Agensys, Boston Biomedical, IderaPharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-Cancer Therapy Evaluation Program, The University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, PharmaMar, Medimmune, advisory board/consultant positions with Helsinn, Incyte, QED Pharma, Daiichi Sankyo, Signant Health, Novartis, Relay Therapeutics, Pfizer, Roche, and Medimmune, travel funds from PharmaMar, Incyte, ASCO, and ESMO, and other support from Medscape outside the submitted work. GC received honoraria for speaker’s engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, MSD; honoraria for providing consultancy: Roche, Seattle Genetics, NanoString; honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; honoraria for writing engagement: Novartis, BMS; honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune. All remaining authors have declared no conflict of interest.
: Not applicable.
: Not applicable.